Navigation Links
Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
Date:5/21/2009

in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.


'/>"/>
SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Celator(R) Pharmaceuticals to Present at 2009 BIO International Convention
2. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
3. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
4. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
5. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
8. Sagent Pharmaceuticals Announces Extension of Series A Financing
9. NSD Bio Group, LLC Selected By U.S. - China Economic & Security Review Commission for Analysis of Chinas Pharma Supply Chain on U.S. Pharmaceuticals
10. Aragon Pharmaceuticals Announces $8 Million Series A Financing
11. Webcast Alert: Isis Pharmaceuticals To Provide General Corporate Update in Conjunction with 2009 Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 The 2014 Warrior-Family Symposium ... Reagan Building and International Trade Center in Washington, ... and Civilian Communities,” will be held from 8:30 ... a.m.) and cohosted by the Military Officers Association ... Association (NDIA). USAA is the Executive Sponsor of ...
(Date:7/22/2014)... By Steven Reinberg ... -- Two treatments that break up blood clots deep in ... of death risk. However, one results in a greater risk ... the cost of the other treatment, a new study finds. ... deep vein thrombosis (DVT) -- is blood-thinning medications and compression ...
(Date:7/22/2014)... minimally invasive hysterectomy using electric power morcellation, uterine cancers ... time of the procedure, according to a study published ... this procedure, in which the uterus is fragmented into ... malignancies. , Despite the commercial availability of electric power ... of malignancy at the time of electric power morcellation ...
(Date:7/22/2014)... -- The American Society of Hematology (ASH) will present ... Award for Lifetime Achievement in Hematology, to Kanti R. ... (LIJ) School of Medicine for his 50-year career combining ... mentoring, and exceptional patient care. , The Wallace ... bestowed on an individual who has been a vital ...
(Date:7/22/2014)... disorders may share certain pathogenic mechanisms with cancer, according ... researcher Linda Kusner, Ph.D. , published in ... shifting work shows that the very same inhibitors of ... in cells that produce autoimmune diseases. Henry Kaminski, ... the GW School of Medicine and Health Sciences (SMHS), ...
Breaking Medicine News(10 mins):Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... and product launch in Southern California is an important stride to ... ... Americans -, TORRANCE, Calif., Sept. 24 Tokyo-based consumer,products company ... first mainstream market in the U.S.,This fall, the probiotic dairy drink will ...
... New findings from researchers at Wake Forest University ... with kidney failure can develop a rare tightening and ... lungs and heart. , Reporting in the October ... suggest a possible explanation for why some patients on ...
... 24 When the Deficit Reduction Act of,2005 ... state Medicaid programs,must demonstrate compliance with the requirement ... or risk losing federal,funding. Under tremendous pressure ... - 90 days, some states already are requiring ...
... Assessment of Impact Underway; Updated Results to Be ... Congress Considers Legislation to Ease Requirements, WASHINGTON, ... of the impact of Medicaid documentation requirements enacted ... of Public Health,and Health Services (GW SPHHS) compiled ...
... Inc. (NYSE: PRX ) invites investors and the,general ... update on the company,s,business strategy and results from 8:30 ... to the live webcast, visit the company,s website homepage ... link. A replay of the,meeting will be available approximately ...
... MetLife Foundation will,begin the next phase of its ... cooperation with the nonprofit Partnership,for a Drug-Free America(R) ... The radio campaign is backed by web resources ... features radio messages, in both English and Spanish,which ...
Cached Medicine News:Health News:Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market 2Health News:New study suggests cause of debilitating skin condition 2Health News:ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 3Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 4Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 2Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 3Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 4
(Date:7/22/2014)... July 22, 2014  PuraMed BioScience®, Inc., (OTCBB: ... (OTC) medicinal and healthcare products, announced today that ... Troop Aid. "We are pleased to ... , CEO and Chairman of PuraMed BioScience. "Research ... combat zones experience migraines much more frequently than ...
(Date:7/22/2014)... July 22, 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, announced today that the U.S. Food and ... Drug, or IND, application.  Such clearance will permit Galmed ... in the United States for ...
(Date:7/22/2014)... 22, 2014 /PRNewswire-iReach/ -- Reproductive Medicine Associates of ... ), a nationally and internationally-recognized leader in providing ... assistance, is pleased to announce a new collaboration with ... Programs to recognize the sacrifices made by veterans and ... Corps Program will allow qualifying veterans and the spouses ...
Breaking Medicine Technology:PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 2Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 3Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 4Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3
... The CKX microscopes utilize the ... visibility and operability in cell ... cost-effective inverted microscope suited to ... of fields--from tissue culture and ...
Continuous rocking motion graphic display....
Stainless steel lockable wall display for up to 12 frames....
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
Medicine Products: